CIA
BMRN icon

Cascade Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cascade Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Buy
26,465
+3,730
+16% +$204K 0.83% 57
2026
Q1 		$1.28M Buy
+22,735
New +$1.33M 0.76% 63

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Cascade Investment Advisors's BMRN Position: Q2 2026 in Review

Cascade Investment Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q2 2026, buying an estimated $204K and bringing the position to 26,465 shares worth $1.51M. The position accounts for 0.83% of the portfolio, ranked #57.

Cascade Investment Advisors first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Cascade Investment Advisors held 26,465 shares of BioMarin Pharmaceuticals worth $1.51M as of Q2 2026.
  • Cascade Investment Advisors bought 3,730 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $204K.
  • BioMarin Pharmaceuticals made up 0.83% of Cascade Investment Advisors's portfolio in Q2 2026, its #57 holding.
  • Cascade Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Cascade Investment Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.